The global pharmaceutical market has thrown up a fascinating anomaly that reveals much about the intersection of health policy, trade barriers, and market efficiency. Canadians can now access Ozempic, the blockbuster diabetes drug, at a fraction of the cost paid by Americans. Meanwhile, the British health service watches from the sidelines, monitoring the growing price disparity across the Atlantic. This is not merely a story of drug pricing. It is a textbook case of how government intervention distorts markets and creates winners and losers.
Let us start with the numbers. In Canada, a month’s supply of Ozempic (semaglutide) costs roughly CAD 200, or about GBP 115. In the United States, the same drug retails for over USD 900, equivalent to GBP 720. That is a sixfold difference. Americans are being stiffed, and they know it. The culprit is a combination of patent protection, lack of price negotiation, and a fragmented insurance system. The Canadian government, by contrast, uses its bulk purchasing power and a national drug agency to keep prices in check.
But here is where it gets interesting. The US Food and Drug Administration has blocked imports of cheaper Canadian Ozempic, citing safety concerns. This is a classic protectionist move dressed up in consumer safety clothing. The US, which prides itself on market freedom, is effectively preventing its citizens from accessing a cheaper, identical product. The result? Capital is flowing out of American pockets and into the coffers of Novo Nordisk, the Danish manufacturer, at a rate that would make a hedge fund manager blush. Shareholders are delighted, but the American taxpayer is footing the bill.
Enter the UK National Health Service. The NHS, never one to miss a bargain, is closely monitoring this transatlantic price gap. But does it have the leverage to act? The NHS is already a bulk buyer, but it operates within a different regulatory framework. The real question is whether the UK can replicate the Canadian model without causing a supply crunch. Canadian pharmacies are already swamped with cross-border demand from American patients. If the NHS were to dip its toe in the Canadian market, prices would bid up, and the arbitrage would vanish.
From a fiscal perspective, the UK has its own problems. The NHS budget is under severe strain, with inflation eroding purchasing power. The latest CPI print shows stubbornly high prices for medical goods, driven in part by global demand for GLP-1 agonists like Ozempic. A cheaper source would be a boon, but it would also set a precedent. If the UK can source Ozempic from Canada, why not other drugs? The pharmaceutical industry would scream bloody murder about intellectual property and supply chain integrity. The Treasury, ever cautious, would warn about unintended consequences.
Meanwhile, the market is voting with its feet. American patients are increasingly turning to online Canadian pharmacies, despite the FDA’s warnings. This is a classic black market in the making, driven by price signals. The US government could close this loophole tomorrow by allowing Medicare to negotiate drug prices, but that would require an act of political will that seems in short supply. As long as the price gap persists, the arbitrage will continue, and the FDA will be fighting a losing battle.
What does this mean for the UK? It is a reminder that the NHS is not immune to global pricing dynamics. The UK already enjoys lower drug prices than the US, thanks to the National Institute for Health and Care Excellence (NICE) cost-effectiveness assessments. But the gap is narrowing. As demand for weight-loss drugs like Ozempic explodes, the NHS will have to decide whether to embrace the Canadian model or accept higher costs. The choice is between market efficiency and fiscal prudence. Given the state of the public finances, I suspect the Treasury will be watching this one very closely indeed.
In conclusion, the Canadian Ozempic bargain is a microcosm of a broken global pharmaceutical market. The US blocks imports to protect its domestic price structure, while the UK watches and waits. The bottom line is simple: price controls and trade restrictions create distortions. The market will find a way around them, but not without cost. For the British patient, the lesson is clear: your health service is a good deal, but it is not immune to the forces of global capital. Keep an eye on those gilt yields, because the cost of healthcare is about to get a lot more expensive.
